biomedion

biomedion is a Germany-based software company that focuses on designing and developing cloud-based enterprise software for the life sciences industry. The company's flagship product, neuronOS®, is a versatile and data-driven life sciences platform which has been implemented by major biotech and pharma companies for over 10 years. The platform ensures data integrity, long-term data archiving, and hybrid architecture, and is designed to fit the F.A.I.R model and help users to be ALCOA+ compliant. In 2023, biomedion made a strategic decision to focus on raw data management, leading to the release of neuronOS® 2.0. As of the 8th of February 2022, the company received a Private Equity Round investment from Main Capital Partners, indicating strong investor confidence in the company's direction and potential for growth. Founded in 2000, biomedion has established itself as a market leader in providing data-driven solutions for the life sciences industry. The company offers a cross-functional product portfolio for managing data integrity from raw data, quality, clinical, and regulatory processes towards retention and archiving. With over 5,000 users, the success of biomedion and its neuronOS® platform demonstrates a strong track record of providing valuable solutions to the industry.